Cargando…

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

Glioblastoma (GBM) is an aggressive and incurable brain tumor in nearly all instances, whose disease progression is driven in part by the glioma stem cell (GSC) subpopulation. Here, we explored the effects of Schlafen family member 11 (SLFN11) in the molecular, cellular, and tumor biology of GBM. CR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischietti, Mariafausta, Eckerdt, Frank, Perez, Ricardo E., Guillen Magaña, Jamie N., Mazewski, Candice, Ho, Sang, Gonzalez, Christopher, Streich, Lukas D., Beauchamp, Elspeth M., Heimberger, Amy B., Baran, Aneta H., Yue, Feng, James, C. David, Platanias, Leonidas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648417/ https://www.ncbi.nlm.nih.gov/pubmed/36382088 http://dx.doi.org/10.1158/2767-9764.CRC-22-0192

Ejemplares similares

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

Human SLFN5 is a Transcriptional Co-repressor of STAT1-Mediated Interferon Responses and Promotes the Malignant Phenotype in Glioblastoma
por: Arslan, Ahmet Dirim, et al.
Publicado: (2017)

Combined PI3Kα-mTOR Targeting of Glioma Stem Cells
por: Eckerdt, Frank D., et al.
Publicado: (2020)

Inhibitory effects of SEL201 in acute myeloid leukemia
por: Kosciuczuk, Ewa M., et al.
Publicado: (2019)

MNK Proteins as Therapeutic Targets in Leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

A novel approach to overcome drug resistance in acute myeloid leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells
por: Saleiro, Diana, et al.
Publicado: (2023)

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
por: Eckerdt, Frank, et al.
Publicado: (2019)

Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
por: Eckerdt, Frank, et al.
Publicado: (2023)

Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells
por: Eckerdt, Frank, et al.
Publicado: (2014)

Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways
por: Mazewski, Candice, et al.
Publicado: (2020)

Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
por: Saleiro, Diana, et al.
Publicado: (2022)

Schlafen 5 as a Novel Therapeutic Target in Pancreatic Ductal Adenocarcinoma
por: Fischietti, Mariafausta, et al.
Publicado: (2021)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

Targeting Cytokines and Their Pathways for the Treatment of Cancer
por: Heimberger, Amy B., et al.
Publicado: (2023)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition
por: Iqbal, Asneha, et al.
Publicado: (2016)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Noncanonical NF-κB in Cancer
por: Tegowski, Matthew, et al.
Publicado: (2018)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts
por: McCord, Matthew, et al.
Publicado: (2022)

HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma
por: Bell, Jonathan B., et al.
Publicado: (2018)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

Targeting Costimulatory Molecules to Improve Antitumor Immunity
por: Capece, Daria, et al.
Publicado: (2012)

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer
por: Brisard, Daphne, et al.
Publicado: (2018)

Regulation of IFNα-induced expression of the short ACE2 isoform by ULK1
por: Perez, Ricardo E., et al.
Publicado: (2022)

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias
por: Curi, Dany A., et al.
Publicado: (2015)

Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
por: Colamonici, Marco, et al.
Publicado: (2015)

Expanding the Interactome of the Noncanonical NF-κB Signaling Pathway
por: Willmann, Katharina L., et al.
Publicado: (2016)

Noncanonical NF-κB Signaling Pathway in Liver Diseases
por: Chen, Qianhui, et al.
Publicado: (2021)

SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
por: Xu, Qiao Ping, et al.
Publicado: (2023)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Characterization of Novel Ribosome-Associated Endoribonuclease SLFN14 from Rabbit Reticulocytes
por: Pisareva, Vera P., et al.
Publicado: (2015)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL
por: Goldshtein, Aviya, et al.
Publicado: (2016)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors
por: Tessitore, Alessandra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r1fjbgqq8h3rk31j3sjo6787al